Exploring The Therapeutic Role of Acebrophylline in Respiratory Diseases: Insights into Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Sripathi Srinivas[1], Dr Pabba Parameshwar[2]
[1]*Research Scholor, Career Point University*
[2]*Research Supervisor, Career Point University*

Abstract: This paper delves into the therapeutic potential of Acebrophylline in the management of respiratory diseases, specifically focusing on its application in asthma and Chronic Obstructive Pulmonary Disease (COPD). Acebrophylline, a xanthine derivative with bronchodilator and anti-inflammatory properties, has garnered attention for its multifaceted actions in the respiratory system. The objective of this review is to provide comprehensive insights into the pharmacological mechanisms, clinical efficacy, and safety profile of Acebrophylline in the context of asthma and COPD. The review begins by elucidating the pathophysiological basis of asthma and COPD, highlighting the intricate interplay of bronchoconstriction, inflammation, and airway remodelling. Subsequently, the pharmacological attributes of Acebrophylline are explored, shedding light on its dual action as both a bronchodilator and an anti-inflammatory agent. This dual mechanism addresses not only the symptomatic relief but also the underlying inflammatory processes associated with these respiratory conditions. Clinical studies investigating the effectiveness of Acebrophylline in asthma and COPD are meticulously examined, encompassing parameters such as improvement in pulmonary function, reduction in exacerbations, and enhancement of quality of life. Furthermore, the safety profile and tolerability of Acebrophylline are critically assessed, providing valuable insights for clinicians and researchers.

Keywords: Acebrophylline, Chronic Obstructive Pulmonary Disease (COPD), anti-inflammatory properties.

INTRODUCTION

Asthma, a chronic respiratory condition characterized by airway inflammation and hyperresponsiveness, exhibits a significant global prevalence, making it a substantial public health concern. According to recent epidemiological data, it is estimated that over 300 million individuals worldwide suffer from asthma, with variations observed across age groups, genders, and geographic regions. The prevalence of asthma tends to be higher in developed countries, but emerging patterns suggest an increasing burden in developing nations as well. The socioeconomic impact of asthma is profound, encompassing both direct and indirect costs. The economic burden on healthcare systems is substantial, driven by expenses related to hospitalizations, medications, and outpatient care. Additionally, asthma imposes a considerable financial strain on individuals and families, with direct medical costs often compounded by indirect costs such as lost productivity due to absenteeism from work or school. The economic repercussions extend beyond the healthcare sector, affecting the overall well-being of communities and nations. However, it is the impact on the quality of life that underscores the multifaceted nature of asthma's consequences. Individuals with asthma often face limitations in their daily activities, ranging from physical exertion to participation in sports or recreational pursuits. School and work absenteeism due to asthma exacerbations contribute to disruptions in education and professional responsibilities, adding to the societal burden. Psychosocially, the condition may lead to increased stress, anxiety, and decreased overall quality of life for both patients and their families.One of the unique challenges in managing asthma lies in its heterogeneity. The diversity in clinical presentations and underlying mechanisms has led to the identification of various phenotypes and endotypes, complicating the categorization and treatment of the disease. Pediatric and adult-onset asthma present distinct challenges, with the former often associated with allergic triggers and the latter potentially linked to occupational exposures or environmental factors.

Chronic Obstructive Pulmonary Disease (COPD) stands as a formidable global health challenge, exerting a substantial impact on individuals, healthcare systems, and economies. With over 328 million people affected globally, COPD represents a major contributor to morbidity and mortality. The prevalence of COPD exhibits geographical variations, with higher rates reported in regions where tobacco smoking, a primary risk factor for the disease, is prevalent. The significance of COPD in global health is underscored by its status as a leading cause of disability and mortality, ranking as the third leading cause of death worldwide. The burden of COPD extends beyond the immediate health implications, permeating into economic and social domains. COPD-related healthcare costs are substantial, encompassing expenditures associated with hospital admissions, pharmacotherapy, and long-term care. Additionally, indirect costs arising from lost productivity due to COPD-related disabilities contribute significantly to the economic burden. As a consequence, COPD exerts a substantial strain on already strained healthcare systems, particularly in low- and middle-income countries where resources may be limited. The health consequences of COPD are severe, with individuals experiencing progressive airflow limitation, exacerbations, and a diminished quality of life. The disease is intricately linked to comorbidities such as cardiovascular diseases and respiratory infections, further complicating its management. The impact on daily activities, employment, and social interactions can be profound, leading to increased disability and a reduced overall quality of life for affected individuals. Distinctive features of COPD, such as chronic inflammation, irreversible airflow limitation, and structural changes in the airways, necessitate a comprehensive and multi-faceted approach to its management. The significance of COPD in global health is further emphasized by the preventable nature of many of its risk factors, including tobacco smoking and occupational exposures. Addressing these modifiable risk factors through targeted public health interventions has the potential to mitigate the burden of COPD and improve overall health outcomes on a global scale.

The prevalence and impact of asthma extend far beyond the physiological manifestations, encompassing economic, social, and psychological dimensions. Understanding these facets is crucial for devising effective public health strategies, improving treatment outcomes, and alleviating the overall burden of asthma on individuals and society. The significance of COPD in global health extends beyond its epidemiological prevalence. It encompasses complex interplays between health, economic, and social factors, highlighting the need for concerted efforts in prevention, early detection, and comprehensive management. Understanding the multifaceted impact of COPD is crucial for developing effective strategies to reduce its prevalence, enhance patient outcomes, and alleviate the strain on global health systems.

Acebrophylline is a bronchodilator and anti-inflammatory drug that holds promise in the management of respiratory conditions, particularly in the context of asthma and Chronic Obstructive Pulmonary Disease (COPD). This xanthine derivative combines the properties of theophylline, a well-established bronchodilator, with the anti-inflammatory actions of ambroxol. The synergistic effects of Acebrophylline make it a unique therapeutic agent, addressing both the bronchoconstriction and the underlying inflammatory processes associated with respiratory diseases. The bronchodilator effects of Acebrophylline are attributed to its ability to relax the smooth muscles in the airways, leading to improved airflow and alleviation of symptoms such as wheezing and shortness of breath. This bronchodilatory action is particularly beneficial in conditions where airway constriction is a key pathological feature, as seen in asthma and COPD. Unlike some traditional bronchodilators, Acebrophylline's mechanism of action is not limited to a specific receptor, allowing for a broader spectrum of activity. Beyond its bronchodilator properties, Acebrophylline exerts anti-inflammatory effects that contribute to its therapeutic efficacy. Inflammatory processes play a crucial role in the pathogenesis of respiratory diseases, leading to airway inflammation and structural changes. Acebrophylline's anti-inflammatory actions involve the inhibition of pro-inflammatory cytokines and mediators, thereby suppressing the chronic inflammatory response. This dual mechanism distinguishes Acebrophylline as a comprehensive therapeutic option, addressing both the symptoms and the underlying inflammatory components of respiratory disorders. Clinical studies have explored the effectiveness of Acebrophylline in improving pulmonary function, reducing exacerbations, and enhancing the quality of life in individuals with asthma and COPD. The drug has demonstrated favorable outcomes in terms of symptomatic relief and disease management, positioning it as a valuable addition to the armamentarium of respiratory medications. Moreover, Acebrophylline's safety profile and tolerability contribute to its suitability for long-term use in chronic respiratory conditions. Acebrophylline stands as a promising therapeutic agent with a dual mechanism of action, combining bronchodilator and anti-inflammatory effects. Its versatility makes it a valuable option for individuals grappling with the challenges of asthma and COPD, offering comprehensive relief by addressing both the acute symptoms and the chronic inflammatory processes associated with these respiratory disorders. Ongoing research continues to unravel the full potential of Acebrophylline, shaping its role in the evolving landscape of respiratory medicine.

PATHOPHYSIOLOGY OF ASTHMA AND COPD

✓ Bronchoconstriction Mechanisms

Bronchoconstriction refers to the narrowing of the airways within the lungs, a process that significantly hampers the normal airflow. Understanding the mechanisms behind bronchoconstriction is crucial in the context of respiratory diseases like asthma and Chronic Obstructive Pulmonary Disease (COPD). The primary factor contributing to bronchoconstriction is the contraction of smooth muscles surrounding the airways. This contraction, triggered by various stimuli, leads to a reduction in the diameter of the bronchioles. Inflammatory processes play a pivotal role in bronchoconstriction. Release of inflammatory mediators, such as histamine, leukotrienes, and prostaglandins, induces smooth muscle contraction and increases the permeability of blood vessels, contributing to the inflammatory response. Excessive production of mucus in the airways is another broncho constrictive mechanism. The thickening of mucus can narrow the air passages, impeding the smooth flow

Inflammation often leads to the swelling of the airway walls, a condition known as airway edema. This swelling further reduces the available space for airflow. Individuals with conditions like asthma often exhibit bronchial hyperresponsiveness, where the airways tend to constrict more easily in response to various stimuli, including allergens, irritants, or exercise. The autonomic nervous system, specifically the parasympathetic nervous system, plays a role in bronchoconstriction. Stimulation of certain receptors, such as muscarinic receptors, can lead to smooth muscle contraction and increased mucus production. Understanding these bronchoconstrictive mechanisms helps in the development of targeted therapies to alleviate symptoms and improve the quality of life for individuals with respiratory conditions. Bronchodilators, which relax the smooth muscles and widen the airways, form a cornerstone in the management of conditions characterized by bronchoconstriction. Additionally, anti-inflammatory medications aim to reduce the underlying inflammation, addressing the root causes of bronchoconstriction in conditions like asthma and COPD.

✓ Inflammatory Processes

Inflammatory processes play a crucial role in the pathophysiology of various respiratory diseases, contributing to symptoms such as airway constriction, mucus production, and tissue damage. Understanding the mechanisms of inflammatory processes is essential in developing effective treatments, particularly in conditions like asthma and Chronic Obstructive Pulmonary Disease (COPD). In response to various triggers such as allergens, pollutants, or infections, immune cells like mast cells and eosinophils become activated. Mast cells release histamine and other inflammatory mediators, initiating the inflammatory cascade. Histamine, leukotrienes, prostaglandins, and cytokines are among the inflammatory mediators released during the inflammatory response. These substances contribute to smooth muscle contraction, increased mucus production, and the recruitment of additional immune cells to the affected area. Inflammatory mediators, particularly histamine, play a central role in inducing the contraction of smooth muscles around the airways. This bronchoconstriction contributes to airflow limitation, a hallmark feature of conditions like asthma. Inflammatory mediators cause blood vessels in the affected area to become more permeable. This increased permeability allows immune cells to migrate to the site of inflammation, contributing to tissue swelling and edema. Inflammatory stimuli trigger the goblet cells in the airways to produce and release excessive mucus. The thickened mucus can obstruct air passages, leading to further difficulty in breathing. Prolonged inflammation can lead to structural changes in the airways, a process known as remodelling. This remodelling involves thickening of the airway walls, fibrosis, and alterations in the structure of the respiratory tissues. Inflammatory processes activate immune cells like neutrophils, macrophages, and T lymphocytes. These cells release additional inflammatory mediators and contribute to the clearance of pathogens, but their prolonged activation can lead to tissue damage. Conditions like asthma and COPD are characterized by chronic inflammation in the airways. This ongoing inflammatory response contributes to the persistence of symptoms, exacerbations, and the progression of the diseases. Understanding the intricate details of inflammatory processes is vital for developing targeted therapies that can modulate the immune response, alleviate symptoms, and potentially modify the course of respiratory diseases. Anti-inflammatory medications, including corticosteroids and other immunomodulatory agents, are commonly employed in the management of conditions marked by chronic inflammation in the respiratory system.

- ✓ Shared and Distinct Features of Asthma and COPD

Asthma and Chronic Obstructive Pulmonary Disease (COPD) are both chronic respiratory conditions that share some common features while exhibiting distinct characteristics. Understanding these shared and unique aspects is crucial for accurate diagnosis and effective management.

Shared Features:

1. Airflow Limitation:

Both asthma and COPD are characterized by airflow limitation, leading to difficulty in breathing. However, the underlying mechanisms and triggers for this limitation differ between the two conditions.

2. Inflammation:

Chronic inflammation is a hallmark of both asthma and COPD. Inflammatory processes contribute to airway narrowing, mucus hypersecretion, and overall respiratory symptoms.

3. Bronchial Hyperresponsiveness:

Individuals with asthma and COPD may exhibit bronchial hyperresponsiveness, where the airways react excessively to various stimuli, resulting in bronchoconstriction.

4. Exacerbations:

Both conditions can experience acute exacerbations, marked by a sudden worsening of symptoms. Exacerbations may be triggered by infections, environmental factors, or other exacerbating agents.

5. Symptoms:

Common symptoms in both asthma and COPD include coughing, wheezing, shortness of breath, and chest tightness. These symptoms may vary in intensity and frequency.

Distinct Features:

1. Onset and Age of Diagnosis:

Asthma often manifests in childhood or early adulthood and is characterized by variable symptoms. COPD typically has a later onset, usually after the age of 40, and progresses slowly over time.

2. Reversibility of Airflow Obstruction:

Asthma is generally characterized by reversible airflow obstruction, with symptoms improving with bronchodilator therapy. In contrast, COPD typically features partially irreversible airflow limitation.

3. Underlying Causes:

Asthma is often associated with allergic reactions and a family history of asthma, while COPD is primarily linked to tobacco smoking, environmental exposures (e.g., occupational dust and chemicals), and genetic factors (alpha-1 antitrypsin deficiency).

4. Airway Remodelling:

Chronic inflammation in asthma can lead to airway remodelling, including changes in the structure of the airways. In COPD, structural changes, such as emphysema and chronic bronchitis, contribute to airflow limitation.

5. Disease Progression:

While both conditions are chronic, asthma tends to have a variable course with periods of exacerbations and remission. COPD often progresses more steadily over time, leading to a gradual decline in lung function.

Recognizing these shared and distinct features is vital for accurate diagnosis and tailoring effective treatment strategies. While both conditions require comprehensive management, the unique aspects of asthma and COPD necessitate individualized approaches to optimize patient outcomes.

PHARMACOLOGICAL MECHANISMS OF ACEBROPHYLLINE

- ❖ Bronchodilator Effects

In respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD), the constriction of airway smooth muscles is a central feature contributing to the hallmark symptoms of airflow limitation and respiratory distress. Bronchodilators, a class of medications specifically designed to alleviate bronchoconstriction, exert their therapeutic effects by playing a crucial role in relaxing airway smooth muscles. The excessive contraction of airway smooth muscles is a result of various stimuli, including exposure to allergens, irritants, or other triggering factors. This heightened smooth muscle tone leads to the narrowing of the air passages, impeding the normal flow of air in and out of the lungs. Bronchodilators, functioning as smooth muscle relaxants, intervene in this process to alleviate the associated symptoms. Beta-agonists, such as albuterol, represent a prominent class of bronchodilators. These medications operate by binding to beta-adrenergic receptors located on the surface of airway smooth muscle cells. Upon binding, a cascade of intracellular events is initiated, culminating in the relaxation of the smooth muscles. This relaxation, in turn, results in the dilation of the bronchioles, effectively widening the airways and restoring normal airflow. In addition to beta-agonists, anticholinergic bronchodilators, such as ipratropium bromide, offer an alternative mechanism of action. These medications inhibit the action of acetylcholine, a neurotransmitter that promotes smooth muscle contraction. By blocking cholinergic activity, anticholinergic bronchodilators induce smooth muscle relaxation, contributing to the dilation of the airways and the alleviation of bronchoconstriction.

The impact of bronchodilators on airway smooth muscles is characterized by its rapid onset of action, providing swift relief during acute episodes of bronchoconstriction. This quality is particularly crucial in managing acute exacerbations or instances of respiratory distress. Moreover, bronchodilators, both short-acting and long-acting, can be employed not only for immediate symptom relief but also as maintenance therapy in chronic respiratory conditions. Long-acting bronchodilators offer sustained smooth muscle relaxation, contributing to the overall management of diseases with persistent bronchoconstriction. The role of bronchodilators in relaxing airway smooth muscles is integral to the comprehensive treatment of respiratory diseases. Their ability to address acute symptoms while also serving as a cornerstone in the long-term management of conditions marked by bronchoconstriction underscores their importance in improving airflow, enhancing respiratory function, and ultimately promoting a better quality of life for individuals affected by these respiratory disorders.

❖ Anti-Inflammatory Properties

In the intricate landscape of respiratory diseases, particularly asthma and Chronic Obstructive Pulmonary Disease (COPD), the impact of bronchodilators on airflow obstruction is paramount. Airflow obstruction, stemming from the constriction of airway smooth muscles and inflammation, presents a significant challenge to individuals afflicted by these conditions. Bronchodilators play a crucial role in mitigating this obstruction and restoring normal airflow. The hallmark of airflow obstruction in respiratory diseases is the narrowing of the bronchioles, limiting the passage of air into and out of the lungs. This narrowing results from the heightened contraction of airway smooth muscles, a process exacerbated by inflammatory mediators. Bronchodilators, acting as smooth muscle relaxants, directly target this constriction, influencing the diameter of the airways and, consequently, the overall airflow. One of the primary classes of bronchodilators, beta-agonists, operates by binding to beta-adrenergic receptors on the smooth muscle cells lining the airways. This interaction triggers a cascade of intracellular events that culminate in smooth muscle relaxation. As the smooth muscles relax, the bronchioles dilate, facilitating the passage of air. This dilation is not only instrumental in relieving the symptoms associated with airflow obstruction, such as wheezing and shortness of breath, but also in improving the overall respiratory function.

In addition to beta-agonists, anticholinergic bronchodilators contribute to the alleviation of airflow obstruction through a different mechanism. These medications, exemplified by ipratropium bromide, inhibit the action of acetylcholine, a neurotransmitter that promotes smooth muscle contraction. By blocking cholinergic activity, anticholinergic bronchodilators induce the relaxation of airway smooth muscles, leading to a widening of the bronchioles and an enhancement of airflow. The impact of bronchodilators on airflow obstruction is particularly noteworthy during acute exacerbations of respiratory conditions. The rapid onset of action of short-acting bronchodilators provides immediate relief, making them indispensable in managing acute episodes of bronchoconstriction. Long-acting bronchodilators, when used as part of maintenance therapy, contribute to sustained smooth muscle relaxation, addressing persistent airflow limitations in chronic respiratory diseases.

❖ Modulation of Inflammatory Mediators

In the intricate landscape of respiratory diseases, the modulation of inflammatory mediators stands as a critical mechanism through which medications, particularly bronchodilators, exert their therapeutic effects. In conditions like asthma and Chronic Obstructive Pulmonary Disease (COPD), chronic inflammation plays a central role in airway constriction, mucus hypersecretion, and overall respiratory symptoms. Bronchodilators, while primarily recognized for their role in relaxing airway smooth muscles, also contribute to the modulation of inflammatory mediators, adding a comprehensive dimension to their therapeutic impact.

1. Beta-Agonists and Inflammatory Mediators:

Beta-agonists, a prominent class of bronchodilators, exert their influence not only on airway smooth muscles but also on inflammatory mediators. By binding to beta-adrenergic receptors on immune cells, including mast cells, beta-agonists interfere with the release of inflammatory substances such as histamine. This modulation helps alleviate the inflammatory response, contributing to the overall reduction of airway hyperresponsiveness and bronchoconstriction.

2. Anticholinergic Bronchodilators and Inflammation:

Anticholinergic bronchodilators, exemplified by ipratropium bromide, impact inflammatory mediators by inhibiting the action of acetylcholine. Acetylcholine, a neurotransmitter, plays a role in activating immune cells and promoting inflammation. By blocking cholinergic activity, anticholinergic bronchodilators help suppress the release of inflammatory substances, thus contributing to the amelioration of airway inflammation.

3. Combination Therapy and Inflammation:

Combination therapy, involving the use of both beta-agonists and corticosteroids, represents an advanced approach to modulating inflammatory mediators comprehensively. While beta-agonists address acute bronchoconstriction, corticosteroids, with their potent anti-inflammatory properties, work to suppress the production of inflammatory cytokines and other mediators. This synergistic approach tackles both the symptoms and the underlying inflammatory processes, optimizing disease management.

4. Long-Acting Bronchodilators and Inflammatory Modulation:

Long-acting bronchodilators, whether beta-agonists or anticholinergics, contribute to sustained inflammatory modulation. Their extended duration of action allows for a prolonged impact on immune cell activity and inflammatory mediator release. This characteristic is particularly valuable in the context of chronic respiratory conditions, where persistent inflammation is a hallmark feature.

5. Addressing Airway Remodelling:

The modulation of inflammatory mediators by bronchodilators also plays a role in addressing airway remodelling, a process where chronic inflammation leads to structural changes in the airways. By mitigating inflammation, bronchodilators contribute to preventing or minimizing the long-term structural alterations associated with conditions like asthma and COPD.

In summary, the modulation of inflammatory mediators represents an additional dimension to the therapeutic repertoire of bronchodilators. Beyond their role in relaxing airway smooth muscles, bronchodilators contribute to the comprehensive management of respiratory diseases by influencing the inflammatory milieu. This dual action highlights the multifaceted nature of bronchodilators in addressing both acute symptoms and the underlying inflammatory processes, fostering improved respiratory function and quality of life for individuals affected by these conditions.

MATERIALS & METHODS

MATERIALS:

In this research work, a range of chemicals were sourced from commercial suppliers, as detailed in table 1. These chemicals, obtained without any additional purification, were of analytical reagent grade, ensuring their suitability for the intended research activities

Table 1: Materials used

S.NO	Chemicals	Source
1	Acebrophylline	UV Scientifics Hyderabad

2	Crospovidone	UV Scientifics Hyderabad
3	Croscarmellosesodium	UV Scientifics Hyderabad
4	Sodiumstarchglycolate	UV Scientifics Hyderabad
5	Sodiumbicarbonate	UV Scientifics Hyderabad
6	Citricacid	UV Scientifics Hyderabad
7	Lactosemonohydrate	UV Scientifics Hyderabad
8	Microcrystallinecellulose	UV Scientifics Hyderabad
9	Mannitol	UV Scientifics Hyderabad
10	Colloidalsilicondioxide	UV Scientifics Hyderabad
11	Magnesiumstearate	UV Scientifics Hyderabad
12	Purifiedtalc	UV Scientifics Hyderabad
13	Aspartame	UV Scientifics Hyderabad
14	Sodiumchloride	UV Scientifics Hyderabad
15	SodiumHydroxide	UV Scientifics Hyderabad
16	WaterforHPLC	UV Scientifics Hyderabad
17	Disodiumhydrogenphosphate	UV Scientifics Hyderabad
18	Acetonitrile	UV Scientifics Hyderabad
19	Ammoniumacetate	UV Scientifics Hyderabad
20	Potassiumbromide	UV Scientifics Hyderabad
21	Hydrochloricacid	UV Scientifics Hyderabad

List of Instruments used

In this research work, various sophisticated instruments were employed to ensure rigorous analysis and data accuracy. The table below offers a detailed list of these instruments, along with their respective model numbers and manufacturers:

Table 2: Instruments used in the research work

S.NO	Instruments	Model & Manufacturer
1	Differential Scanning Calorimetry	DSC-60,Shimadzu,Japan
2	FT-IR Spectrometer	NicoletiS5,ThermoScientific
3	Water Purification Plant	Milli-QAcademic,Milli-Pore.
4	Verniercalliper	Dalian Mingfeng Machinery
5	Hardness tester	Monsanto.
6	TabletFriabilater	Rochefriabilator (ERWEKA).
7	HPLC	Shimadzu,Japan
8	MechanicalStirrer	RQT-124A,Remi.
9	DigitalpHmeter	EutechInstruments
10	DisintegrationTestApparatus	H-7500,Hitachi.
11	DissolutionTestApparatus USPTypeII	Electrolab
12	Centrifuge	C-24,Remi.
13	Tabletpunchingmachine	10stations,Erweka, Germany

DRUG PROFILE

ACEBROPHYLLINE

Description

ACEBROPHYLLINE belongs to the bronchodilator class of medications and is primarily utilized for the prevention and management of symptoms associated with asthma and chronic obstructive pulmonary disease (COPD).

In individuals with asthma, the airways tend to constrict, become inflamed, and produce an excess of mucus, leading to difficulties in breathing. Asthma is recognized as a chronic (long-term) respiratory disorder. The COPD umbrella encompasses conditions such as emphysema and chronic bronchitis, both of which result in shortness of breath.

Acebrophylline functions by relaxing the muscles around the airways in the lungs, facilitating their opening. In addition to its bronchodilator properties, ACEBROPHYLLINE serves as a mucolytic agent, assisting in the thinning and expulsion of phlegm (mucus) from the nasal passages, windpipe, and lungs. This dual action not only eases the act of coughing but also enhances respiratory efficiency.

Chemical/Physical Properties of Acebrophylline

Acebrophylline is obtained through the targeted salification of trans-4(2-amino-3,5 dibromobenzylamino) cyclohexanol, which is the base of ambroxol, and theophylline 7 acetic acid.

The process involves the salification of the carboxyl group of theophylline 7 acetic acid with the amine group of ambroxol. This combination is done in a specific stoichiometric ratio that ensures post-absorption high blood concentrations of ambroxol alongside a minimal amount of the xanthine derivative. Yet, this minimal xanthine derivative concentration is adequate to guarantee a transport effect for ambroxol. Specifically, the composition consists of 38.7% acid and 61.3% base.

Furthermore, studies have shown that lung concentrations of the drug are enhanced by 45% one hour post-administration, compared to administration of only ambroxol. This highlights the synergistic effect and enhanced delivery potential of acebrophylline, making it effective in treating conditions like asthma and COPD.

Structural Formula:



MolecularFormula : C22H28Br2N6O5
MolecularWeight : 616.3 g/moL
ChemicalName : 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetic acid

Mechanism of Action of Acebrophylline

Acebrophylline, a complex molecule, exhibits a multi-modal mechanism of action due to its unique composition derived from theophylline-7-acetate and ambroxol.

1. Bronchial Muscle Relaxation: Theophylline-7-acetate inhibits intracellular phosphodiesterases, leading to an increase in the levels of cyclic AMP (adenosine monophosphate). Elevated cyclic AMP promotes the relaxation of bronchial smooth muscles. This aids in the widening of the airways, allowing for easier breathing, which is beneficial in conditions like asthma and COPD.
2. Mucociliary Clearance: Ambroxol acts as a mucolytic agent. One of its primary mechanisms is the enhancement of cilia motility present in the respiratory tract. Improved cilia motility, in turn, boosts mucociliary clearance. This means mucus (or phlegm) is moved more effectively out of the airways, reducing its build-up and facilitating easier breathing.
3. Anti-inflammatory Action: Acebrophylline exhibits anti-inflammatory properties. It mitigates inflammation by suppressing the synthesis and release of inflammatory mediators such as leukotrienes and tumor necrosis factor (TNF). By doing so, it reduces inflammation in the airways, which can be especially beneficial in chronic respiratory conditions where inflammation is a primary concern.

Pharmacodynamics of Acebrophylline

Acebrophylline exhibits a complex pharmacodynamic profile, playing a pivotal role in mediating bronchial muscle relaxation and attenuating inflammation. Here's a breakdown:

1. Bronchial Muscle Relaxation: Acebrophylline acts on intracellular phosphodiesterases, leading to an inhibition of these enzymes. This action subsequently elevates the levels of cyclic AMP (cAMP) within the cells. The rise in cAMP promotes the relaxation of bronchial smooth muscles, facilitating the dilation of the airways. This is particularly beneficial in conditions like asthma and COPD where bronchoconstriction is a primary concern.

Anti-inflammatory Action:

- Phospholipase A and Phosphatidylcholine Inhibition: Acebrophylline selectively inhibits phospholipase A and phosphatidylcholine. These enzymes play a role in the breakdown of phospholipids, leading to the release of arachidonic acid. Arachidonic acid can be further metabolized to produce various pro-inflammatory mediators. By inhibiting these enzymes, Acebrophylline curtails the production of these inflammatory agents.
- Inhibition of TNF-alpha and Leukotrienes: Tumor Necrosis Factor-alpha (TNF-alpha) and leukotrienes are significant pro-inflammatory mediators. Acebrophylline suppresses the synthesis and release of TNF-alpha and leukotrienes. By doing so, it provides an anti-inflammatory effect that helps in reducing inflammation, especially in the airways. This property is particularly beneficial in conditions like asthma and COPD, where inflammation exacerbates the disease state.

Pharmacokinetics of Acebrophylline

Pharmacokinetics refers to the movement of drugs within the body and includes absorption, distribution, metabolism, and excretion (often abbreviated as ADME). Here's a detailed breakdown of the pharmacokinetics of Acebrophylline:

1 Absorption:

- After oral administration, Acebrophylline is absorbed from the gastrointestinal tract. The rate and extent of absorption can be influenced by factors such as food intake, dosage form, and other concomitant medications.

2 Distribution:

- Once absorbed, Acebrophylline is widely distributed throughout the body. It can penetrate various tissues and organs, ensuring its therapeutic action at the desired sites. Factors like protein binding, blood flow to tissues, and molecular size can influence its distribution.

3 Metabolism:

- The liver primarily metabolizes Acebrophylline. Here, the drug undergoes biotransformation, which means it is converted into metabolites. These metabolites can either be active, possessing therapeutic effects of their own, or inactive.

4 Excretion:

- The primary route of excretion for Acebrophylline and its metabolites is through the urine. The kidneys play a pivotal role in filtering out the drug and ensuring its elimination from the body. The rate of excretion can be influenced by factors like renal function and urine pH.

Absorption and Distribution Note: Acebrophylline's absorption and distribution are crucial aspects of its pharmacokinetic profile. Proper absorption ensures therapeutic concentrations of the drug in the blood, while its wide distribution ensures that the drug reaches the target tissues, such as the lungs, to exert its therapeutic effects.

5 Onset of Action:

- Acebrophylline: The onset of action, which refers to the time it takes for a drug to produce a therapeutic response after administration, is approximately 1 to 2 hours for Acebrophylline. This means that after oral intake, patients can expect to experience its therapeutic effects, such as bronchodilation and anti-inflammatory actions, within this timeframe.

6 Half-Life:

- Acebrophylline: The half-life, indicating the time required for the concentration of the drug in the body to be reduced by half, is approximately 4 to 9 hours for Acebrophylline. This duration is significant for determining dosing intervals. The half-life gives an indication of how long the drug's effects last and how frequently it should be administered to maintain therapeutic levels in the bloodstream.

7 Side Effects of Acebrophylline

Like all medications, Acebrophylline can cause side effects, although not everyone will experience them. Here's a list of some potential side effects associated with Acebrophylline:

8 Gastrointestinal Side Effects:

1. Abdominal Discomfort: Some patients may experience discomfort or pain in the abdominal area after taking the medication.
2. Stomach/Abdominal Distension: There could be a feeling of fullness or swelling in the stomach or abdomen.
3. Vomiting: Some patients might experience nausea followed by the urge to vomit.
4. Diarrhea: An increase in frequency and liquidity of stools might occur.
5. Constipation: Some patients may have infrequent bowel movements or difficulty in passing stools.
6. Esophageal Bleeding: Although rare, there might be bleeding in the esophagus, which can be identified by vomiting blood or dark, tar-like stools.

9 Contraindications of Acebrophylline

Contraindications refer to specific situations in which a drug should not be used because it may be harmful to the patient. Here are the contraindications for Acebrophylline:

1. Hypersensitivity to Ambroxol and Xanthine Derivatives: Patients who have had allergic reactions or show hypersensitivity to Ambroxol (a component of Acebrophylline) or any xanthine derivatives should avoid taking Acebrophylline.
2. Myocardial Infarction: Acebrophylline is contraindicated in patients who have recently experienced a heart attack or myocardial infarction.
3. Hypotension: Patients with abnormally low blood pressure should avoid Acebrophylline, as it might further reduce blood pressure or exacerbate related symptoms.

4. Renal Disease: Patients with kidney diseases or reduced kidney function should exercise caution as the drug and its metabolites are excreted through the kidneys.
5. Liver Disorder: Since Acebrophylline is metabolized in the liver, individuals with liver diseases or impaired liver function should avoid this medication or use it under close medical supervision.
6. Hemodynamic Instability: Patients who have unstable blood circulation or are hemodynamically unstable should not take Acebrophylline.
7. Arrhythmias: Individuals with irregular heart rhythms or arrhythmias should avoid Acebrophylline, as xanthine derivatives can potentially exacerbate these conditions.

10 Special Precautions while taking Acebrophylline

When taking Acebrophylline, certain conditions require special attention and monitoring due to the potential increased risk of side effects or complications. Here are the special precautions to consider:

1. Cardiac Insufficiency: Patients with heart conditions, especially those with reduced heart pumping efficiency, should be cautious when taking Acebrophylline. It's essential to monitor heart function and ensure that the medication does not exacerbate the condition.
2. Gastrointestinal Disorders: Individuals with pre-existing gastrointestinal issues may be at a higher risk of experiencing or exacerbating stomach-related side effects. It's advisable to monitor for signs of abdominal discomfort, vomiting, diarrhea, or other digestive issues.
3. Epilepsy: Acebrophylline may lower the seizure threshold in individuals with epilepsy, potentially increasing the risk of seizures. Patients with epilepsy should use Acebrophylline under close medical supervision, and any changes in seizure patterns should be promptly reported.
4. Hyperthyroidism: Patients with an overactive thyroid (hyperthyroidism) may be more sensitive to the side effects of Acebrophylline, especially cardiac-related ones. It's essential to monitor thyroid hormone levels and adjust medication dosages accordingly.

The DSC thermograms of both the pure Acebrophylline drug and its mixtures with various excipients were acquired following the standard procedure. The results are visually represented in Figures.

Pure Drug: The DSC analysis of Acebrophylline alone exhibited an endothermic peak at 268°C. This value is proximate to its reported melting point of 270°C.

Mixture with Super Disintegrant Additives: This mixture displayed an endothermic peak at 269.1°C.

Mixture with Effervescence Approach Additives: An endothermic peak was observed at 269.5°C.

Mixture with Sublimation Approach Additives: The thermogram indicated an endothermic peak at 269.8°C.

Upon analysing the DSC thermograms, it's evident that:

There's minimal variance in the endothermic peak values among the pure drug and its mixtures with excipients.

There were no pronounced alterations in the thermograms, such as peak shifts, or the emergence or disappearance of peaks.

The subtle deviations in the endothermic peaks among the pure drug and its mixtures, along with the absence of significant changes in the thermograms, suggest that there's no evident chemical interaction between Acebrophylline and the selected excipients. The consistency of the DSC patterns further reinforces the compatibility between the drug and the chosen excipients, ensuring the potential stability of the resultant formulations.



Figure 1DSCgraphofpureAcebrophylline



Figure 2DSC graph of Acebrophylline with crospovidone, croscarmellose sodium and sodium starch glycolate



Figure 3DSC graph of Acebrophylline with sodium bicarbonate and citric acid



Figure 4DSC graph of Acebrophylline with camphor

Chemical Stability Assessment with FTIR

The FTIR spectrometer was utilized to analyse samples following the outlined procedure. Both the drug and excipients' IR spectra displayed expected absorption bands. Furthermore, physical mixtures exhibited characteristic peaks of both the drug and excipients without any significant alterations, indicating no discernible chemical interactions. The stability and compatibility of the drug and excipients are thus confirmed. Refer to Figures 6.5 to 6.8 for the corresponding FTIR spectra.



Figure 5FTIR spectra of pure Acebrophyllin



Figure 6FTIR spectra of Acebrophylline with crospovidone, cross carmellose sodium and sodium starch glycolate



Figure 7FTIR spectra of Acebrophylline with sodium bicarbonate and citricacid

CONCLUSION

In conclusion, the study and understanding of bronchodilators, particularly their role in relaxing airway smooth muscles and modulating inflammatory mediators, unveil their crucial position in the management of respiratory diseases. Bronchodilators, including beta-agonists and anticholinergics, play a pivotal role in relieving bronchoconstriction by inducing the relaxation of airway smooth muscles. This mechanism directly addresses the airflow obstruction characteristic of conditions like asthma and Chronic Obstructive Pulmonary Disease (COPD), providing rapid relief during acute episodes and forming a cornerstone of maintenance therapy. Moreover, bronchodilators contribute to the modulation of inflammatory mediators, presenting a comprehensive approach to disease management. Beta-agonists, by interfering with the release of inflammatory substances, and anticholinergic bronchodilators, by inhibiting cholinergic activity, contribute to the suppression of the inflammatory response. This dual action not only alleviates acute symptoms but also addresses the underlying inflammatory processes, offering a more holistic approach to the treatment of respiratory diseases.

REFERENCE

[1] Leung JM, Sin DD. Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets. BMJ 2017; 358: j3772.
[2] Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of

Disease Study 2016. Lancet 2017; 390: 1211–1259.
[3] Uchida A, Sakaue K, Inoue H. Epidemiology of asthma-chronic obstructive pulmonary disease overlap (ACO). Allergol Int 2018; 67: 165–171.
[4] Menezes AMB, Montes de Oca M, Perez-Padilla R, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest 2014; 145: 297–304.
[5] Miravitlles M, Soriano JB, Ancochea J, et al. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Respir Med 2013; 107: 1053–1060.
[6] Kim M, Tillis W, Patel P, et al. Association between asthma-COPD overlap syndrome and healthcare utilizations among US adult population. Curr Med Res Opin 2019; 35: 1191–1196.
[7] Rootmensen G, van Keimpema A, Zwinderman A, et al. Clinical phenotypes of obstructive airway diseases in an outpatient population. J Asthma 2016; 53: 1026–1032.
[8] Hirai K, Shirai T, Suzuki M, et al. A clustering approach to identify and characterize the asthma and chronic obstructive pulmonary disease overlap phenotype. Clin Exp Allergy 2017; 47: 1374–1382.
[9] Bourdin A, Suehs CM, Marin G, et al. Asthma, COPD, and overlap in a national cohort: ACO on a gradient. J Allergy Clin Immunol 2018; 141: 1516–1518.
[10] James AL, Wenzel S. Clinical relevance of airway remodelling in airway diseases. Eur Respir J 2007; 30: 134–155.
[11] Global Initiative for Asthma (GINA). Diagnosis of diseases of chronic airflow limitation: asthma, COPD and asthma-COPD overlap syndrome (ACOS). 2015. https://ginasthma.org/asthma-copd-and-asthma-copd-overlapsyndrome-acos/
[12] Bourbeau J, Bhutani M, Hernandez P, et al. CTS position statement: pharmacotherapy in patients with COPD-An update. Can J Respir Crit Care Sleep Med 2017; 1: 222–241.
[13] Yanagisawa S, Ichinose M. Definition and diagnosis of asthma-COPD overlap (ACO). Allergol Int 2018; 67: 172–178.
[14] Kankaanranta H, Harju T, Kilpeläinen M, et al. Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the Finnish guidelines. Basic Clin PharmacolToxicol 2015; 116: 291–307.
[15] Plaza V, Alvarez F, Calle M, et al. Consensus on the asthma-COPD overlap syndrome (ACOS) between the Spanish COPD guidelines (GesEPOC) and the Spanish guidelines on the management of asthma (GEMA). Arch Bronconeumol 2017; 53: 443–449.
[16] Cazzola M, Rogliani P. Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? J Allergy Clin Immunol 2016; 138: 977–983.
[17] Kostikas K, Clemens A, Patalano F. The asthma-COPD overlap syndrome: do we really need another syndrome in the already complex matrix of airway disease? Int J Chron Obstruct Pulmon Dis 2016; 11: 1297–1306.
[18] Rodrigo GJ, Neffen H, Plaza V. Asthma-chronic obstructive pulmonary disease overlap syndrome: a controversial concept. Curr Opin Allergy Clin Immunol 2017; 17: 36–41.
[19] Perez-de-Llano L, Cosio BG, CHACOS study group. Asthma-COPD overlap is not a homogeneous disorder: further supporting data. Respir Res 2017; 18: 183.
[20] Miravitlles M, Alvarez-Gutierrez FJ, Calle M, et al. Algorithm for identification of asthma-COPD overlap: consensus between the Spanish COPD and asthma guidelines. Eur Respir J 2017; 49: 1700068.